Standard BioTools Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Standard BioTools Inc. (LAB) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$15.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-16
- Standard BioTools Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$15.00M, a 108.32% decline from fiscal 2024.
- Standard BioTools Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $180.30M.
- Standard BioTools Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was $9.90M, a 800.00% increase from fiscal 2020.
- Standard BioTools Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2020 was $1.10M, a 72.50% decline from fiscal 2019.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | -$15.00M 10-K · filed 2026-03-16 |
| 2024-12-31 | $180.30M 10-K · filed 2026-03-16 |
| 2021-12-31 | $9.90M 10-K · filed 2022-03-08 |
| 2020-12-31 | $1.10M 10-K · filed 2022-03-08 |
| 2019-12-31 | $4.00M 10-K · filed 2021-02-25 |
| 2018-12-31 | $6.90M 10-K · filed 2021-02-25 |
| 2017-12-31 | -$27.10M 10-K · filed 2020-02-27 |
| 2016-12-31 | $22.10M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |